• Exact Sciences (NasdaqCM:EXAS), Amalgam Rx, and Privia Health rolled out a nationwide, EHR-enabled outreach program focused on colorectal cancer screening.
• The program uses Exact Sciences' Cologuard test integrated into electronic health records to reach and engage at-risk patients at scale.
• According to the case study, participating groups recorded colorectal cancer screening rates that outperformed national benchmarks and goals.
• The initiative also reports lower staff workload by automating patient identification, engagement, and follow-up for at-home Cologuard testing.

For investors watching NasdaqCM:EXAS, this case study offers another data point on how the company’s Cologuard test fits into real world care delivery. Exact Sciences is focused on noninvasive cancer screening, and this kind of embedded EHR workflow is increasingly common as health systems look for ways to reach more patients with fewer administrative steps.

What stands out here is the emphasis on scalability, from patient outreach to follow-up and quality measurement. If similar programs are adopted more widely, you could see more attention on how Exact Sciences' products integrate with digital health tools and population health efforts across large physician networks.

Stay updated on the most important news stories for Exact Sciences by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Exact Sciences.

Investor Checklist

Quick Assessment

• ⚖️ Price vs Analyst Target: At US$103.50, the share price is about 2.2% below the US$105.81 analyst consensus target, which sits well inside the forecast range of US$105 to US$118.
• ✅ Simply Wall St Valuation: Simply Wall St currently estimates the shares are trading about 31.3% below fair value.
• ✅ Recent Momentum: The 30 day return of roughly 1.2% shows modest positive momentum into this CRC screening news.

There is only one way to know the right time to buy, sell or hold Exact Sciences. Head to the Simply Wall St company report for the latest analysis of Exact Sciences's Fair Value.

Key Considerations

• 📊 This nationwide, EHR enabled outreach program highlights how Cologuard can be embedded into large scale care workflows, which may be important for thinking about test adoption and recurring use.
• 📊 Given the valuation flag and this use case, you might watch how CRC testing volumes, partnerships with health systems and any updates on reimbursement or EHR integrations evolve.
• ⚠️ With a current P/E of about 95x versus an industry average near 21x and a recent net income loss of US$207.9m, execution risk on growth programs like this remains a key factor.

Dig Deeper

For the full picture including more risks and rewards, check out the complete Exact Sciences analysis. Alternatively, you can visit the community page for Exact Sciences to see how other investors believe this latest news will impact the company's narrative.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.